MedTrace Logo

The Safety, Tolerability, and Pharmacokinetics (PK) of SR750 in Healthy Volunteers

NCT05083468 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 83

Last updated 2024-11-29

No results posted yet for this study

Summary

This study is to evaluate the safety, tolerability, and PK of SR750 in healthy volunteers.

Conditions

  • Healthy Volunteers

Interventions

DRUG

SR750 tablet

The volunteers will be orally administrated by single or multiple dose of SR750 tablet with 240 mL water.

DRUG

matching placebo

The volunteers will be orally administrated by single or multiple dose of matching placebo with 240 mL water.

Sponsors & Collaborators

  • Shanghai SIMR Biotechnology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Cameron Johnson · Nucleus Network Pty Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-10-29
Primary Completion
2022-10-14
Completion
2022-10-14

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05083468 on ClinicalTrials.gov